APA (7th ed.) Citation

B, L., S, B., JW, K., C, D., E, H., G, J., . . . HM, S. (2024). Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024. MMWR. Morbidity and mortality weekly report, 73(45), 1015. https://doi.org/10.15585/mmwr.mm7345a1

Chicago Style (17th ed.) Citation

B, Lefferts, et al. "Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024." MMWR. Morbidity and Mortality Weekly Report 73, no. 45 (2024): 1015. https://doi.org/10.15585/mmwr.mm7345a1.

MLA (9th ed.) Citation

B, Lefferts, et al. "Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024." MMWR. Morbidity and Mortality Weekly Report, vol. 73, no. 45, 2024, p. 1015, https://doi.org/10.15585/mmwr.mm7345a1.